Skip To Main Content
Yin Wang on Muck Rack

Yin Wang

As seen in: Arthritis & Rheumatology, Nature, Wiley, Wiley Online Library, arXiv, British Pharmacological Society, PLOS ONE, ScienceDirect, BMJ Open, Frontiers and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yin

Contact Yin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Machine learning prediction of mitral regurgitation improvement after TAVI

|
By Peng Liu, Zirui Zhao, Hanzhe Wang, Junlin Lai, Xiang Qiu, Xiaojing Li, Shijie Wang, Yin Wang, Yazheng Shan
| Nature Verified
Abstract The fate of mitral regurgitation after transcatheter aortic valve implantation is highly heterogeneous, and accurate preoperative prediction of mitral regurgitation improvement remains challenging. This study aimed to develop and validate a machine learning-based predictive model for regurgitation improvement following transcatheter aortic valve implantation.
Open in Who Shared Issue with article?

Fucoidan from Pearsonothuria graeffei alleviates dyslipidemia in ApoE −/− mice by regulating reverse cholesterol transport and promoting bile acid synthesis

|
By Ting Zhao, Yang Yu, Yin Wang, Liyang Zhang, Junqi Xiao, Shiguo Chen, Shan Li
| Frontiers in Nutrition
Abstract Background: The fucoidan extracted from sea cucumber Pearsonothuria graeffei (Fuc-Pg) has beneficial anti-inflammatory and lipid-lowering effects, suggesting its potential anti-atherosclerotic properties. Methods: ApoE−/− mice were fed a high-fat diet (HFD) for 12 weeks. Fuc-Pg (20 mg/kg and 80 mg/kg) was administered by oral gavage once daily.
Open in Who Shared Issue with article?

KRAS/ERK2-driven stabilization of AARS1 reprograms tumor metabolism and confers Sorafenib resistance in lung adenocarcinoma

|
By Wenxuan Hu, Zhike Chen, Jian Yang, Gaomeng Luo, Haoyang Yuan, Kang Hu, Xin Lv, Yin Wang, Jun Zhao, Chun Xu
| Nature Verified
Abstract KRAS is the most frequently mutated oncogene in human cancers, and its G12C variant is highly prevalent in lung adenocarcinoma (LUAD) and predicts poor clinical outcomes. However, the metabolic mechanisms underlying KRAS-driven malignancy and therapeutic resistance remain incompletely understood. Here, we identify alanyl-tRNA synthetase 1 (AARS1) as a previously unrecognized metabolic effector of KRAS signaling.
Open in Who Shared Issue with article?
See all 198 licensed articles (206 Total)